Regulus Therapeutics (NASDAQ:RGLS) Shares Pass Above Two Hundred Day Moving Average of $1.66

Shares of Regulus Therapeutics Inc. (NASDAQ:RGLS) passed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $1.66 and traded as high as $2.67. Regulus Therapeutics shares last traded at $2.51, with a volume of 562,862 shares traded.

Analysts Set New Price Targets

Several research firms have recently commented on RGLS. StockNews.com began coverage on shares of Regulus Therapeutics in a report on Tuesday, April 16th. They issued a “sell” rating on the stock. Canaccord Genuity Group decreased their price target on shares of Regulus Therapeutics from $12.00 to $11.00 and set a “buy” rating on the stock in a research note on Tuesday, March 19th. Leerink Partnrs reaffirmed an “outperform” rating on shares of Regulus Therapeutics in a research note on Monday, March 18th. SVB Leerink started coverage on shares of Regulus Therapeutics in a research note on Monday, March 18th. They set an “outperform” rating and a $6.00 price target on the stock. Finally, Wells Fargo & Company upped their price target on shares of Regulus Therapeutics from $2.00 to $3.00 and gave the company an “equal weight” rating in a research note on Wednesday, March 13th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $7.25.

Regulus Therapeutics Stock Up 9.1 %

The firm has a market cap of $164.32 million, a PE ratio of -1.58 and a beta of 1.57. The company’s 50 day moving average price is $2.26 and its two-hundred day moving average price is $1.66.

Regulus Therapeutics (NASDAQ:RGLS) last announced its earnings results on Thursday, March 21st. The biopharmaceutical company reported ($0.40) earnings per share for the quarter, meeting the consensus estimate of ($0.40). On average, analysts expect that Regulus Therapeutics Inc. will post -0.52 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Victory Capital Management Inc. grew its holdings in shares of Regulus Therapeutics by 5.3% in the third quarter. Victory Capital Management Inc. now owns 233,207 shares of the biopharmaceutical company’s stock worth $322,000 after purchasing an additional 11,701 shares during the last quarter. FMR LLC grew its holdings in Regulus Therapeutics by 32.4% during the 3rd quarter. FMR LLC now owns 2,922,600 shares of the biopharmaceutical company’s stock worth $4,033,000 after acquiring an additional 716,000 shares in the last quarter. Finally, Vivo Capital LLC bought a new position in Regulus Therapeutics during the 1st quarter worth about $14,400,000. 92.38% of the stock is currently owned by institutional investors.

Regulus Therapeutics Company Profile

Regulus Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease.